BioCentury
ARTICLE | Clinical News

MGCD516: Interim Phase I data

October 19, 2015 7:00 AM UTC

Interim data from 28 patients with advanced solid tumors in the Phase I portion of an open-label, dose-escalation, U.S. Phase I/Ib trial showed that once-daily 10, 20, 40, 80, 110 and 150 mg doses of ...